Longitudinal Quality-of-Life Outcomes of Skull Base Chondrosarcoma Patients following Surgical Resection
Journal of Neurological Surgery Part B: Skull Base · 01.08.2025 · 86 (04) · 429-437
DOI: 10.1055/a-2360-9857 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurological Surgery Part B: Skull Base, erschienen am 01.08.2025. Verfasst von Seika Taniguchi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Owing to the rarity of skull base chondrosarcomas (CS), much of its natural history and long-term impact on patient quality of life (QoL) are not well studied. This novel study demonstrates QoL among CS patients following radical treatment constituting surgery and postoperative radiotherapy over 2 decades. Study Design Retrospective review and prospective data collection to obtain patient demographic, tumor characteristics, clinical symptoms, and patient-reported QoL outcomes using the 36-Item Short Form Health Survey (SF-36). Setting/Participants Patients diagnosed with CS who underwent radical intent surgical resection by the senior author and adjuvant early postoperative proton beam therapy.
Results
Twenty-eight skull base CS patients were identified, with 19 patients completing full treatment course. Mean long-term follow-up was 148.9 months. Diplopia symptom resolution was high. No significant deterioration in SF-36 Physical Health Component (PHC) and Mental Health Component (MHC) scores was observed at postoperative and long-term follow-up. General health was stable initially but deteriorated in long term (Δ −18.88, minimal clinically important difference [MCID]: 9.86, p = 0.04). Compared with age-matched Canadian control patients, CS patients reported similar PHC scores at baseline and follow-up. CS patients reported lower MHC scores (45.8 vs. 50.9, p = 0.13) preoperatively, which persisted at follow-up decreasing by 1.9 (43.9 vs. 53.7, p = 0.03); this difference, however, did not reach MCID threshold of Δ 5.9.
Conclusion
We present the longest follow-up data on CS demonstrating stable long-term QoL with aggressive surgery. Tumor control was high and preoperative tumor size did not affect long-term QoL. Preoperative QoL was lower among CS compared with Canadian normative data. Postoperatively, only the decline in physical functioning QoL scores exceeded MCID. At long-term follow-up, the decline in physical functioning, social functioning, and general health exceeded MCID. Overall, QoL among CS patients remained lower at long-term follow-up despite absence of tumor progression and resolution of symptoms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
- Division of Neurosurgery, Department of Surgery, Vancouver General Hospital, Vancouver, BC, Canada.
- Department of Neurosurgery, Royal Melbourne Hospital, Melbourne, Victoria Australia.
ORCID-Profile: Seika Taniguchi
Zitieren
APA
Taniguchi, S., Kam, J., Kirszbaum, C. M., & Akagami, R. (2025). Longitudinal Quality-of-Life Outcomes of Skull Base Chondrosarcoma Patients following Surgical Resection. Journal of Neurological Surgery Part B: Skull Base, 86(04), 429-437. https://doi.org/10.1055/a-2360-9857
Vancouver
Taniguchi S, Kam J, Kirszbaum CM, Akagami R. Longitudinal Quality-of-Life Outcomes of Skull Base Chondrosarcoma Patients following Surgical Resection. Journal of Neurological Surgery Part B: Skull Base. 2025;86(04):429-437. doi:10.1055/a-2360-9857
BibTeX
@article{Taniguchi2025,
author = {Taniguchi, Seika and Kam, Jeremy and Kirszbaum, Castle-Mendel and Akagami, Ryojo},
title = {Longitudinal Quality-of-Life Outcomes of Skull Base Chondrosarcoma Patients following Surgical Resection},
journal = {Journal of Neurological Surgery Part B: Skull Base},
year = {2025},
volume = {86},
number = {04},
pages = {429--437},
doi = {10.1055/a-2360-9857}
}
EUVIMED